Document Detail


Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.
MedLine Citation:
PMID:  2340503     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The noncycling cell compartment of tumors is considered to be an important target for chemotherapeutic agents; yet, it has been difficult to accurately quantitate its contribution to tumor response because of a lack of methods that can readily discern the relative sensitivities of cycling and noncycling cells. We have used antibodies against bromodeoxyuridine-substituted DNA in a unique experimental protocol that provides a basis for distinguishing the cycling and noncycling cell compartments and detecting their respective levels of drug-induced chromosome damage. A mixed population of cycling and noncycling cells was obtained by culturing 9L rat brain tumor cells as multicellular spheroids. Cell cycle compartments and phase distributions were monitored with flow cytometry using bivariate analysis of DNA content and bromodeoxyuridine incorporation. Bromodeoxyuridine labeling was manipulated to differentially label metaphases from cycling and noncycling cells for sister chromatid exchange. This is based on the differential staining patterns of chromatids and metaphases that are obtained from cells that have replicated in the presence of bromodeoxyuridine. The chromosome damage in each cell cycle compartment following exposure to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea was assessed by the number of sister chromatid exchanges induced by treatment. Noncycling cells were shown to be more sensitive to 1,3-bis(2-chloroethyl)-1-nitrosourea-induced damage than were cycling cells. However, when allowed to remain noncycling for 24 h after treatment, the number of exchanges decreased in noncycling cells, which may indicate their ability to recover from damage. These results illustrate an experimental protocol that permits simultaneous assessment of cell cycle compartment recruitment and sister chromatid exchange induction in cells derived from a cytokinetically complex population containing both cycling and noncycling cells.
Authors:
M H Barcellos-Hoff; L J Marton; D F Deen
Related Documents :
17362983 - Can the cardiomyocyte cell cycle be reprogrammed?
9759963 - The cell division cycle and the pathophysiology of alzheimer's disease.
24526893 - A comparative study on root canal repair materials: a cytocompatibility assessment in l...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  50     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1990 Jun 
Date Detail:
Created Date:  1990-06-25     Completed Date:  1990-06-25     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3551-5     Citation Subset:  IM    
Affiliation:
Department of Neurological Surgery, School of Medicine, University of California, San Francisco 94143-0520.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Brain Neoplasms / drug therapy,  genetics,  pathology*
Bromodeoxyuridine / diagnostic use*,  metabolism
Carmustine
Cell Cycle / drug effects*
DNA Damage*
DNA, Neoplasm / analysis,  biosynthesis*,  drug effects,  metabolism
Rats
Sister Chromatid Exchange / drug effects*
Time Factors
Tumor Cells, Cultured / drug effects,  pathology
Grant Support
ID/Acronym/Agency:
CA-13525/CA/NCI NIH HHS; CA-42779/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/DNA, Neoplasm; 154-93-8/Carmustine; 59-14-3/Bromodeoxyuridine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desac...
Next Document:  Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and...